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Abstract
It has long been recognized that the modification of penicillin-binding proteins (PBPs) to reduce their affinity for b-lactams
is an important mechanism (target modification) by which Gram-positive cocci acquire antibiotic resistance. Among Gram-
negative rods (GNR), however, this mechanism has been considered unusual, and restricted to clinically irrelevant laboratory
mutants for most species. Using as a model Pseudomonas aeruginosa, high up on the list of pathogens causing life-
threatening infections in hospitalized patients worldwide, we show that PBPs may also play a major role in b-lactam
resistance in GNR, but through a totally distinct mechanism. Through a detailed genetic investigation, including whole-
genome analysis approaches, we demonstrate that high-level (clinical) b-lactam resistance in vitro, in vivo, and in the clinical
setting is driven by the inactivation of the dacB-encoded nonessential PBP4, which behaves as a trap target for b-lactams.
The inactivation of this PBP is shown to determine a highly efficient and complex b-lactam resistance response, triggering
overproduction of the chromosomal b-lactamase AmpC and the specific activation of the CreBC (BlrAB) two-component
regulator, which in turn plays a major role in resistance. These findings are a major step forward in our understanding of b-
lactam resistance biology, and, more importantly, they open up new perspectives on potential antibiotic targets for the
treatment of infectious diseases.
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Introduction
Decades after their discovery, b-lactams remain key components
of our antimicrobial armamentarium for the treatment of infectious
diseases. Bacterial resistance to them is generally driven either by
theproductionofenzymesthat inactivate them(b-lactamases),orby
the modification of their targets in the cell wall (penicillin-binding
Proteins, PBPs), sometimes in conjunction with mechanisms leading
to diminished permeability or active efflux [1].
While the acquisition of modified PBPs showing low affinity for
b-lactams is well known to be a major resistance mechanism in
Gram-positive cocci, such as penicillin-resistant Streptococcus
pneumoniae or the much-feared methicillin-resistant Staphylococcus
aureus, this mechanism has not been thought to be important for
most species of Gram-negative rods (GNR) [2]. The production of
intrinsic or horizontally acquired b-lactamases is undoubtedly the
predominant resistance mechanism in the latter organisms [3].
Among GNRs, the most widely distributed b-lactamases are
chromosomally-encoded AmpC variants, produced by most
Enterobacteriaceae and Pseudomonas aeruginosa, high up the list of
pathogens causing life-threatening infections in hospitalized
patients world-wide [4].
Although AmpC is produced at very low basal levels in wild-
type strains, its expression is highly inducible in the presence of
certain b-lactams (b-lactamase inducers) such as cefoxitin or
imipenem [3]. In fact, the efficacy of the widely-used broad
spectrum penicillins (such as piperacillin) and cephalosporins (such
as ceftazidime) relies on the fact that they are very weak AmpC
inducers, even though they are efficiently hydrolyzed by this
enzyme [3]. Unfortunately, mutants showing constitutive high
level AmpC production (AmpC derepressed mutants) are
frequently selected during treatment with these b-lactams, leading
to the failure of antimicrobial therapy [5,6]. In some natural
strains of Enterobacteriaceae and P. aeruginosa [6–9], the inactivation
of AmpD (cytosolic N-acetyl-anhydromuramyl-L-alanine amidase
involved in peptidoglycan recycling [10–12]), and point mutations
in AmpR (LysR-type transcriptional regulator required for ampC
induction [13–15]) have been found to lead to AmpC overexpres-
sion, and thus to b-lactam resistance.
In this paper we show that, in contrast to the current
expectations, the mutations triggering b-lactam resistance in P.
aeruginosa, whether in vitro, in vivo, or in the clinical setting,
frequently arise within a PBP gene. Inactivation of the E. coli dacB
ortholog, encoding the nonessential low molecular mass PBP4
PLoS Pathogens | www.plospathogens.org 1 March 2009 | Volume 5 | Issue 3 | e1000353[16,17], is demonstrated to be the principal route to one-step high
level (clinical) b-lactam resistance, by triggering the overexpression
of ampC and the specific activation of the CreBC two component
regulator [18], which is also found to play a major role in
resistance.
Results/Discussion
Mutation of P. aeruginosa PBP4 is the main driver of one-
step high-level b-lactam resistance in vitro and in vivo
The mechanisms by which b-lactam resistance arises were
studied in a previously described [19] collection of 36 independent
ceftazidime resistant mutants. These mutants were obtained in vitro
(one-step spontaneous mutants) or in vivo (after 3 days of treatment
with humanized ceftazidime regimen in mouse model of lung
infection), at two ceftazidime concentrations (4 and 16 mg/ml),
and from the wild-type strain PAO1 (normal mutation rate supply)
or its mutS deficient hypermutable derivative PAODmutS (high
mutation rate supply). In the previous study, all the mutants were
shown to be highly resistant to all tested penicillins, cephalospo-
rins, and monobactams; overexpression of the chromosomal
cephalosporinase AmpC (18 to 236-fold higher expression relative
to wild-type) was found to be the instrument of b-lactam resistance
in all cases.
In this work, in an attempt to find out the genetic mechanisms
leading to AmpC hyperproduction, we sequenced and quantified
the expression of all genes so far known to be involved in ampC
regulation and overexpression (ampD, ampE, ampDh2, ampDh3 and
ampR) in the 36 mutants. We also performed complementation
experiments with plasmids harboring the wild-type ampD gene
(pUCPAD) or the complete ampDE operon (pUCPADE). A
complete report of the obtained results is provided in Table S1.
In contrast to present models, almost none of the mutants (32 of
36) showed mutations in any of the loci examined. The only
exceptions were 4 mutants obtained in vivo from PAODmutS (high
mutation rate supply) at the low ceftazidime concentration (4 mg/
ml), each showing a different mutation in ampD. A modified
expression of any of the studied genes was neither observed in the
32 mutants. As expected, only the four ampD mutants showed
positive complementation with pUCPAD, but, intriguingly, all the
36 mutants showed positive complementation with pUCPADE
(Table S1). Furthermore, positive complementation required the
simultaneous presence of both ampD and ampE, since plasmids
harboring ampDE operons with a non functional ampD and a wild-
type ampE also failed to complement the resistance phenotype.
These findings suggested that, contrary to current understanding,
mutations in ampD or ampR are not at all the most common, in vitro
orinvivo,leadingtoAmpCoverexpressionand highlevel(clinical)b-
lactam resistance in P. aeruginosa. Furthermore, the results strongly
suggest that one-stephigh-levelceftazidime resistanceinP. aeruginosa
mainly occurs through single mutations in a gene/genes previously
unknown to be involved in b-lactam resistance or AmpC regulation.
That a single mutation has to be responsible for the resistance
phenotype is shown by the ceftazidime resistance mutation rates
published previously [19]. At two different ceftazidime concentra-
tions (4 and 16 mg/ml), spontaneous resistant mutants were
obtained with a rate of 10
28 mutations per cell division for wild-
type PAO1 and of 10
25210
26 for PAODmutS. These mutation
rates should rule out the involvement of more than one mutation in
the resistance phenotype.
In an attempt to detect the mutations in the gene(s) yet unknown
to be involved in b-lactam resistance, we followed a whole-genome
analysis approach. Four of the PAO1 ceftazidime resistant in vitro
mutants were analyzed by comparative hybridization on a recently
described microarray for the discovery of single nucleotide
polymorphisms (SNPs) in P. aeruginosa [20] using the parental
PAO1 strain as reference. As shown in Figure 1, major decreases in
hybridization ratios (indicating deletions of 50–100 base pairs) were
detected for two of the mutants in the gene PA3047, the E. coli dacB
ortholog, encoding the nonessential low molecular mass PBP4
[16,17]. PCR and sequencing confirmed the presence of the
deletions in this gene [(nts 1149–1231 for one of the mutants (1A5)
and nts 1069–1138 for the other (1D7)] (Figure 1, Table S1).
Furthermore, the two remaining mutants (1A1 and 1D4) also
revealedalesspronounceddecrease ofhybridizationratioatasingle
position in gene PA3047 (Figure 1); PCR and sequencing identified
as well the mutations, a G to A change in nt 819 leading to a
premature stop codon (W273X) for 1A1 and a A to C change in nt
235 leading to a missense mutation (T79P) for 1D4 (Table S1).
The function and structure of PBP4 (DacB) has been
characterized mainly in E. coli. The protein is a nonessential low
molecular mass class C PBP with DD-carboxypeptidase and DD-
endopeptidase activity, that is thought to play an auxiliary role in
morphology maintenance, peptidoglycan maturation and recy-
cling, and cell separation during division [17,21,22]. The crystal
structure of E. coli PBP4 has been recently determined [16] and
found to be organized in three domains. Domain I has the
characteristic SXXK, SXN, and KTG motifs of PBPs and b-
lactamases, and contains the other two extra domains embedded
within it. PBP4 from P. aeruginosa shows a 27% identity with that of
E. coli, and contains all conserved motifs. The alignment of E. coli
and P. aeruginosa PBP4 sequences is included in Figure S1.
Following the discovery of mutations within the dacB ortholog,
we sequenced this gene in the rest of the collection of the 36
ceftazidime resistant mutants, and the complete list of the
mutations detected is provided as Table S1. All but 2 of the 32
mutants not having mutations in ampD had mutations in dacB.A
total of 28 different mutations were detected, and included
deletions/insertions (9), nonsense mutations (7), and missense
mutations (12). Many of the missense mutations occurred in
sequences encoding highly conserved motifs, including the
catalytic serine, at position 72 in P. aeruginosa (Figure S1, Table S1).
Author Summary
Decades after their discovery, b-lactams remain key
components of our antimicrobial armamentarium for the
treatment of infectious diseases. Nevertheless, resistance
to these antibiotics is increasing alarmingly. There are two
major bacterial strategies to develop resistance to b-
lactam antibiotics: the production of enzymes that
inactivate them (b-lactamases), or the modification of their
targets in the cell wall (the essential penicillin-binding
proteins, PBPs). Using the pathogen Pseudomonas aerugi-
nosa as a model microorganism, we show that high-level
(clinical) b-lactam resistance in vitro and in vivo frequently
occurs through a previously unrecognized, totally distinct
resistance pathway, driven by the mutational inactivation
of a nonessential PBP (PBP4) that behaves as a trap target
for b-lactams. We show that mutation of this PBP
determines a highly efficient and complex b-lactam
resistance response, triggering overproduction of the
chromosomal b-lactamase AmpC and the specific activa-
tion of a two-component regulator, which in turn plays a
key role in resistance. These findings are a major step
forward in our understanding of b-lactam resistance
biology, and, more importantly, they open up new
perspectives on potential antibiotic targets for the
treatment of infectious diseases.
New b-Lactam Resistance Pathway
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lactam resistance, we constructed the dacB knockout mutant of
PAO1 (PADdacB). As shown in Table 1, the inactivation of dacB in
PAO1 yielded an almost identical phenotype to that documented
in the ceftazidime-resistant dacB spontaneous mutants, with high
level b-lactam resistance and ampC overexpression. Therefore, it is
for the first time demonstrated that the inactivation of a particular
PBP (which are supposed to be antibiotic targets) produces high-
level b-lactam resistance.
Mutation of P. aeruginosa PBP4 determines an AmpR-
dependent overexpression of the b-lactamase AmpC
In order to understand the role of PBP4 mutation in b-lactam
resistance and upregulation of AmpC expression, we constructed
the ampC, ampR (transcriptional regulator of AmpC), ampD (negative
regulator of AmpC) and ampE (second component of the bicistronic
ampDE operon, encodes an inner membrane-bound sensory
transducer that modulates AmpD activity [23]), knockout mutants
of strain 1A1 (DacB W273X in vitro spontaneous mutant of PAO1)
andofstrainPAO1ascontrol. AsshowninTable 1,the inactivation
of ampC completely restored ceftazidime susceptibility in 1A1,
showing that the overexpression of the b-lactamase is essential for
the resistance phenotype. Furthermore, the inactivation of ampR
restored ceftazidime susceptibility and basal ampC expression levels,
thus demonstrating that the effect of PBP4 mutation requires a
functional AmpR. Therefore, considering that PBP4 has been
shown to be involved in peptidoglycan recycling [17] it seems
reasonable to believe that ampC overexpression driven by dacB
inactivation, as occurs in the classical ampD mutation pathway,
should be consequence of the qualitative or quantitative modifica-
tion of muropeptides, that are the effector molecules for AmpC
induction through their interaction with AmpR [24]. Our results
are also consistent with previous observations in the E. coli model, in
which the strongest AmpC inducers (such as imipenem) were shown
to be potent PBP4 inhibitors, suggesting a role of this PBP in the
induction process [25].
Additionally, we show that the AmpDE pathway of AmpC
repression is functional in the PBP4 mutants, since the inactivation
of ampD dramatically increased further ampC expression and
ceftazidime resistance in 1A1 (Table 1). Furthermore, while the
inactivation of ampE in PAO1 (or in its ampD mutant) did not
produce significant effects, it also determined a marked increase of
ampC expression and ceftazidime resistance in the dacB mu-
tant.These results suggest that both genes of the ampDE operon
play a major role in the dacB mutant background. This conclusion
is further supported by the positive complementation of the PBP4
mutants with the complete ampDE operon expressed from a
multicopy plasmid (Table 2). Moreover, the expression of dacB
from a multicopy plasmid (pUCPdB) also complemented both, the
dacB and the ampD mutants (Table 2). Therefore, these results
show that PBP4 and AmpDE are parallel synergic ampC regulatory
pathways (a defect in one of them can be complemented by
increasing the amount of the other), both ultimately relying on a
functional AmpR.
While both pathways have a very similar effect on ampC
expression, PBP4 mutation confers high level (clinical) b-lactam
resistance (i.e. resistant according to current breakpoints), while
ampD inactivation confers only moderate resistance (i.e. still
susceptible according to current resistance breakpoints) (Table 1).
In fact, the resistance level conferred by PBP4 mutation is more
similar to that conferred by the simultaneous inactivation of the
three ampD genes of P. aeruginosa (ampD plus the two additional
homologous genes, ampDh2 and ampDh3 [26]), that produces a
much higher increase in ampC expression (Table 1). Nevertheless,
this mechanism of high-level resistance is not found among clinical
strains [27,28], because it requires the acquisition of several
mutations and because it causes a marked reduction of fitness and
virulence [27]. Here we show that in vivo (murine systemic infection
model) fitness is not affected in the PAO1 dacB mutant, as shown
by the competition index (CI) of 0.92, in sharp contrast to the
previously documented CIs of less than 0.01 for the double and
triple ampD mutants [27]. Therefore, in contrast to the ampD
Figure 1. Comparative genome hybridization of four spontaneous ceftazidime-resistant mutants revealing mutations in gene
PA3047. Genomic DNA from mutants 1A1, 1A5, 1D4, and 1A7 was analyzed on a whole genome DNA tiling microarray and compared to the
parental wildtype PAO1. Data points (stems) represent the log2 ratio of signal intensity of each mutant against the wildtype signal. Mutants 1A5 and
1A7 showed strong decreases in signal at three consecutive positions (*), indicating deletions. In mutant 1A1 and 1D4, a slight decrease in signal (+)
pointed towards a small genetic change, e.g., a single point mutation.
doi:10.1371/journal.ppat.1000353.g001
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efficient one-step trigger of high level b-lactam resistance
mechanism of potentially enormous clinical relevance.
Mutation of P. aeruginosa PBP4 specifically triggers the
activation of the CreBC two-component regulator, which
in turn plays a major role in resistance
In order to explore further the effects of PBP4 mutation, we
performed a whole-genome analysis of gene expression in two
selected mutant strains (1A1 and 2A2) compared to wild-type
PAO1, using the Affymetrix GeneChip P. aeruginosa genome array.
In addition to ampC (and co-transcribed PA4111), which obviously
was upregulated, only one further gene showed a significantly (.2-
fold change) modified expression. This gene, creD, was upregulated
in both mutants analyzed (not shown). creD encodes an inner
membrane protein of yet unknown function that is regulated by
the CreBC two-component regulator. The CreBC system has been
deeply studied in E. coli, and it is shown to be a global regulator
involved in metabolic control [18]. Interestingly, the homolog of
Table 1. Susceptibility to b-lactams and expression of ampC and creD genes in the studied mutants.
Straina MIC (mg/ml)
b,c ampC Expression
d,e creD Expression
d,e
CAZ CEP PIP PIP/TZ ATM IMP Basal Induced Basal Induced
PAO1 1.5 1.5 4 2 2 1.5 1 50614 1 36617
PADC 1122 2 0 . 5 N A N A N D N D
PADR 2264 3 0 . 5 3 . 8 60.4 3.360.8 1.660.1 18968
PADD 844 8 3 2 6 24 8 641 3 4 611 1.160.1 2.760.7
PADE 1.5 1.5 4 3 2 1.5 21.560.2 4264 2.361.6 49629
PADDE 12 4 48 32 6 2 23681 4 5 643 ND ND
PADDDh2Dh3 48 24 .256 .256 24 1.5 1,020687 1,105688 1.360.3 1.660.7
PADDDh2Dh3R 2264 3 0.38 ND ND 1.260.1 284676
PADdacB 32 16 128 64 16 2 21611 232667 8367 120629
1A1 (DacB W273X) 32 16 128 48 16 2 58692 1 1 655 53612 112634
1A1DC 0.75 0.75 1.5 1 1.5 0.38 NA NA ND ND
1A1DR 1.5 1.5 4 3 2 0.38 1.560.1 1.460.1 4761 103614
1A1DD 128 64 .256 .256 48 2 1,7706414 1,9506480 51624 81640
1A1DE9 6 6 4 .256 .256 32 2 296666 6656228 58613 78629
2A2 (DacB frameshift) 32 16 96 64 16 2 34616 199654 27612 150629
PADcreBC 1.5 1.5 4 3 2 2 1.660.2 68617 1.160.1 1.360.2
PADDDh2Dh3creBC 48 24 .256 .256 24 2 2,5806492 2,8906268 2.060.5 2.460.7
1A1DcreBC 4 4 24 12 4 2 40622 1 0 638 1.060.1 1.360.4
2A2DcreBC 4 4 32 12 4 2 42615 149667 1.260.1 1.260.2
1A1DcreD 24 12 64 32 8 2 ND ND NA NA
aPAO1, wild-type reference strain; PADC, ampC knockout mutant of PAO1; PADR, ampR knockout mutant of PAO1; PADD, ampD knockout mutant of PAO1; PADE, ampE
knockout mutant of PAO1; PADDE, ampD-ampE knockout mutant of PAO1; PADDDh2Dh3, ampD triple (ampD-ampDh2-ampDh3) knockout mutant of PAO1;
PADDDh2Dh3R, ampR knockout mutant of PADDDh2Dh3; PADdacB, dacB knockout mutant of PAO1; 1A1 (DacB W273X), DacB W273X in vitro spontaneous mutant of
PAO1; 1A1DC, ampC knockout mutant of 1A1; 1A1DR, ampR knockout mutant of 1A1; 1A1DD, ampD knockout mutant of 1A1; 1A1DE, ampE knockout mutant of
1A1;2A2 (DacB frameshift), in vivo spontaneous mutant of PAO1 containing a deletion of nts 1074–1078 in dacB;P A DcreBC, creBC knockout mutant of PAO1;
PADDDh2Dh3creBC, creBC knockout mutant of PADDDh2Dh3creBC; 1A1DcreBC, creBC knockout mutant of 1A1; 2A2DcreBC, creBC knockout mutant of 2A2; 1A1DcreD,
creD knockout mutant of 1A1.
bCAZ, ceftazidime; CEP, cefepime; PIP, piperacillin; PIP/TZ, piperacillin-tazobactam; ATM, aztreonam; IMP, imipenem.
cClinical Laboratory Standards Institute (CLSI) susceptibility breakpoints: CAZ, CEP, and ATM#8 mg/ml; PIP and PIP/TZ#64 mg/ml; IMP#4 mg/ml.
dRelative amount of ampC or creD mRNA compared to PAO1 basal level6standard deviation. Induction experiments were carried out with 50 mg/ml cefoxitin.
eNA, not applicable; ND, not determined.
doi:10.1371/journal.ppat.1000353.t001
Table 2. Results of the complementation experiments of the PAO1 ampD and dacB mutants with different plasmids.
Straina Ceftazidime MICs (mg/ml) When Producing the Plasmid
None pUCP24 (Vector) pUCPAD (ampD) pUCPADE (ampDE) pUCPdB (dacB)
PAO1 1.5 1.5 1.5 1.5 1.5
PADD 8 8 1.5 1.5 1.5
PADdacB 32 32 24 1.5 1.5
aPAO1, wild-type reference strain; PADD, ampD knockout mutant of PAO1; PADdacB, dacB (PBP4) knockout mutant of PAO1.
doi:10.1371/journal.ppat.1000353.t002
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play a role in the regulation of b-lactamase expression in these
species [29–31]. As first approach, we analyzed whether creD
overexpression was a signature feature of the PBP4 mutants.
Indeed, real time RT-PCR experiments confirmed the overex-
pression of this gene in the two selected mutants (Table 1) as well
as in the complete collection of in vivo and in vitro PBP4 mutants,
with creD mRNA levels ranging from 25 to 60-fold higher than
those of wild-type PAO1 (not shown). Moreover, the inactivation
of dacB in wild-type PAO1 produced a similar creD overexpression
(Table 1). The effect on creD expression seemed to be specific for
the PBP4 mutants, rather than a direct consequence of AmpC
overexpression, since this gene was not upregulated in the ampD
mutants (Table 1). Interestingly, creD expression in wild-type
PAO1 was found to be highly inducible by b-lactamase inducers
(cefoxitin) (Table 1). Furthermore, creD inducibility was signifi-
cantly reduced in the ampD mutants and the reduction in
expression was dependent on a functional AmpR, since its
inactivation restored the inducibility (Table 1). Overall, these
results suggested a link between the CreBC regulator, PBP4
mutations, and the components of the regulatory system of ampC
expression.
The complete creB, creC and creD genes, as well as their promoter
regions, were fully sequenced in 1A1, 2A2 and five additional
randomly selected mutants from the collection. The absence of
mutations supported further the notion that the mutations in PBP4
are solely responsible for the complete b-lactam resistance
response. The single mutation hypothesis is definitively confirmed
by the fact that direct dacB inactivation produces the same
phenotype (i.e. the same MICs and ampC and creD expression
levels) observed in the spontaneous dacB mutants.
To gain insights into the role of the CreBC system in b-lactam
resistance, we constructed creBC and creD knockout mutants of the
PBP4 mutants 1A1 and 2A2, as well as of PAO1 and its single and
triple ampD mutants as controls. Interestingly, the inactivation of
creBC in the PBP4 mutants (1A1 and 2A2) not only decreased creD
expression back to wild-type levels, but also drastically decreased
b-lactam MICs, leaving them well within the susceptible (treatable)
range according to current breakpoints (Table 1). Furthermore,
the effect was specific to the PBP4 mutants, since b-lactam
susceptibility was not affected by creBC inactivation in wild-type
PAO1 or in its ampD mutants (Table 1). Overall, these results
strongly suggest that PBP4 mutations specifically trigger the
activation of the CreBC two-component regulator, leading to creD
upregulation and b-lactam resistance. Nevertheless, CreD seems
not to be the only CreBC-dependent driver of resistance, since the
direct inactivation of creD in the PBP4 mutants decreased
resistance slightly, but did not give the drastic reduction seen on
CreBC inactivation (Table 1). The extra resistance of the PBP4
mutants compared to the ampD mutant (despite showing similar
levels of ampC expression) is therefore apparently driven by the
specific activation of the CreBC system in the PBP4 mutants.
Indeed, the resistance level of 1A1 after CreBC inactivation was
more similar to that of the ampD mutant (Table 1). Further
evidence showing that the CreBC system is a key component in
one-step high level b-lactam resistance development was provided
by mutation rates experiments. While high level ceftazidime
resistant mutants were readily selected from PAO1 wild-type strain
[mutation rate to ceftazidime (at breakpoint concentration, 16 mg/
ml) resistance of 3610
28 mutants per cell division], mutation rates
were below the detection limit (,1610
211) for its CreBC knockout
mutant (PADCreBC), consistently with the interpretation that a
functional CreBC system is required for one-step high level
(clinical) b-lactam resistance development in P. aeruginosa.
Nevertheless, in contrast to the previous experiences with the
BlrAB system in Aeromonas Spp., CreBC mediated resistance was
not directly driven by an effect on ampC expression, since
1A1DCreBC (despite showing a drastic reduction of resistance)
had similar (still overexpressed) ampC levels than the parent 1A1
(Table 1). Moreover, b-lactamase activity was also similar (data
not shown), showing that apparently the effect is neither produced
by posttranscriptional modification of AmpC. Therefore, although
we demonstrate that mutation of PBP4 specifically activates the
CreBC two-component regulator, and that this event plays a
major role in b-lactam resistance, the underlying mechanism is still
uncertain. Despite only creD showed a modified expression greater
2-fold in the transcriptome analysis, even small modifications of
expression of genes involved in outer membrane permeability,
antibiotic efflux or general metabolism could significantly enhance
the effect of AmpC overexpression and thus b-lactam resistance.
In any case, our findings indicate that the nomenclature for this
two-component system in P. aeruginosa should be changed to follow
that used for Aeromonas Spp. (Blr, standing for b-lactam resistance)
and not that used in E. coli (Cre, standing for carbon-source
responsive) [18,29–31].
Figure 2 summarizes the current knowledge on P. aeruginosa
ampC regulation, peptidoglycan recycling, and the described
similarities and differences of the b-lactam resistance response
driven by AmpD inactivation or PBP4 mutation.
Role of PBP4 mutation in the clinical setting
To find out whether PBP4 mutations and the linked CreBCD
mediated resistance documented for in vitro and in vivo mutants
occurred also in natural human infections, we investigated a
previously described collection of clinical strains [6]. This
collection included 10 isogenic pairs of ceftazidime susceptible
and resistant clinical isolates obtained from 10 Intensive Care Unit
patients. All patients had severe P. aeruginosa infections that were
treated with b-lactams, experiencing therapy failure due to
resistance development. In all cases, the subsequent ceftazidime
resistant isolate showed AmpC hyperproduction, but only in four
of them could the resistance phenotype be attributed to known
mechanisms (ampD mutations) [6]. As shown in Table 3, all 6
remaining ceftazidime isolates contained mutations in dacB (not
present in the preceding isogenic susceptible isolate). Interestingly,
two of the isolates (despite them being genetically distinct) have
sustained the same PBP4 mutation (T428P); this same mutation
was found in one of the PAO1 in vivo mutants (Table S1) and
involves a conserved residue close to the KTG motif [16].
Furthermore, consistent with the findings for in vitro and in vivo
mutants, all six natural PBP4 mutants overexpressed creD (2.8–38
fold higher expression than their respective wild-type isolates)
(Table 3). The inactivation of creBC significantly reduced
ceftazidime resistance in all but one of the natural PBP4 mutants
(Table 3). On the other hand, the expression of creD was not
modified in the four clinical strains containing only mutations in
ampD (not shown).
Concluding remarks
Using P. aeruginosa as a model organism, we have shown that the
most prevalent mutations causing immediate onset of high level b-
lactam resistance are found in the dacB gene, encoding the
nonessential PBP4. This is the first demonstration of the
acquisition of b-lactam resistance through such a mechanism.
All the previous examples by which PBP-mediated resistance
develops involve modified enzymes showing low affinity for b-
lactams (target modification) [2]. Even though inactivation of the
classical AmpC negative regulator AmpD upregulates AmpC, only
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The inactivation of PBP4 is found to trigger an AmpR-dependent
overproduction of the chromosomal b-lactamase AmpC, and the
specific activation of the CreBC (BlrAB) two-component regulator,
which in turn plays a major role in the b-lactam resistance
response. This interplay between mutation of supposed antibiotic
targets, production of antibiotic inactivating enzymes, and global
regulators, is an unexpected layer of complexity of b-lactam
resistance biology, which provides new perspectives on potential
antibiotic targets for the treatment of infectious diseases. Since all
the components of the described resistance mechanism (dacB,
ampC, ampR, and creBCD) are found in the genomes of many GNR
(E. coli might be an example of exception since ampR is not present
in this species [14]), the results presented here are expected to have
broad implications for the development of new antimicrobial
compounds. Particularly, the CreBCD system is envisaged as an
attractive candidate target to develop molecules capable of
reducing the development of resistance when used together with
b-lactam antibiotics.
Materials and Methods
Bacterial strains and plasmids
A complete list of laboratory strains and plasmids used or
constructed in this study is provided as Table S2. A previously
described [19] collection of 36 independent ceftazidime resistant
mutants was used. These mutants were obtained either in vitro
(one-step spontaneous mutants) or in vivo (after 3 days of treatment
with humanized ceftazidime regimen in mouse model of lung
infection), at two ceftazidime concentrations (4 and 16 mg/ml),
and from the wild-type strain PAO1 (normal mutation rate supply)
or its mutS deficient derivative PAODmutS (high mutation rate
supply). Additionally, a previously reported [6] collection of 10
isogenic pairs of ceftazidime susceptible and resistant clinical
Figure 2. Schematic representation of the regulation of the P. aeruginosa chromosomal b-lactamase AmpC and peptidoglycan
recycling under different conditions. (A) Wild-type strain in the absence of b-lactams. During regular bacterial growth, the peptidoglycan
degradation products, MurNac-peptides [N-acetylglucosaminyl-1,6-anhydro- N-acetylmuramyl-tri (or tetra) peptides], are generated in the periplasm
through the activity of PBP4 and several other enzymes. These products are then internalized through the permease AmpG, and processed in the
cytoplasm by the b-N-acetylglucosaminidase NagZ and the N-acetyl-anhydromuramyl-L-alanine amidase AmpD. P. aeruginosa has two additional
AmpD proteins, AmpDh2 that it is apparently located in the outer membrane and AmpDh3 that is still of unknown location. The generated
tripeptides are then incorporated to the murein biosynthesis pathway to yield the UDP-MurNac-pentapeptides that will be exported to the periplasm
and incorporated to the peptidoglycan, to complete the recycling process. In the absence of b-lactam antibiotics, these UDP-MurNac-pentapeptides
interact with AmpR, which functions as a negative regulator of ampC expression. (B) Growth of wild-type strain in the presence AmpC inducer b-
lactams. During growth in the presence of certain b-lactams (AmpC inducers), such as cefoxitin or imipenem, AmpC is produced at high levels,
conferring natural (intrinsic) resistance to the antibiotic, provided it is a good substrate for the enzyme (as occurs for cefoxitin but not for imipenem).
The exact mechanism responsible for the induction of the expression of AmpC in the presence of these antibiotics is still not fully understood. One of
the components of the induction process is apparently the saturation of AmpD, due to the enhanced generation of its substrate (MurNac-
tripeptides). The accumulated MurNAc-tripeptides are thought to displace the UDP-MurNAc-pentapeptides from AmpR, converting it into an
activator of ampC transcription. Our results, and other previous indirect evidences, suggest that the inhibition of PBP4 by these b-lactam antibiotics
(known to be the most potent PBP4 inhibitors) plays a major role in the ampC induction process, and determines the activation of the CreBC (BlrAB)
two-component regulator. The exact function of the signal transducer AmpE, located in the inner membrane, still needs to be elucidated, but
apparently interacts with both AmpD and PBP4. (C) Growth of the AmpD and/or PBP4 mutants in the presence of AmpC non-inducer b-lactams (most
antipseudomonal cephalosporins and penicillins, such as ceftazidime or piperacillin, respectively). The inactivation of PBP4 or AmpD produces a very
similar constitutive ampC overexpression. Both mechanisms ultimately relay in the activation of AmpR, which changes its activity from negative to
positive regulator of ampC expression. Independently of the mechanism, AmpC overexpression itself is shown to confer only moderate (low-level)
acquired resistance to non-inducer b-lactams. Additionally, the inactivation of PBP4 specifically activates the CreBC (BlrAB) system, which drives, in
conjunction with the AmpC overexpression, the high-level b-lactam resistance response.
doi:10.1371/journal.ppat.1000353.g002
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from severe P. aeruginosa infections was used.
Construction of knockout mutants
P. aeruginosa single or multiple knockout mutants in ampD, ampE,
ampR, ampC, creBC, creD,o rdacB were constructed using the Cre-lox
system for gene deletion and antibiotic resistance marker recycling
[32]. Upstream and downstream PCR products (primers used
provided as Table S3) of each gene were digested with either
BamHI or EcoRI and HindIII and cloned by a three way ligation
into pEX100Tlink deleted for the HindIII site and opened by
EcoRI and BamHI. The resulting plasmids were transformed into
E. coli XL1Blue strain and transformants were selected in 30 mg/
ml ampicillin LB agar plates. The lox flanked gentamicin resistance
cassette (aac1) obtained by HindIII restriction of plasmid
pUCGmlox was cloned into the single site for this enzyme formed
by the ligation of the two flanking fragments. The resulting
plasmids were again transformed into E. coli XL1Blue strain and
transformants were selected in 30 mg/ml ampicillin-5 mg/ml
gentamicin LB agar plates. Plasmids were then transformed into
the E. coli S17-1 helper strain. Knockout mutants were generated
by conjugation followed by selection of double recombinants using
5% sucrose-1 mg/ml cefotaxime-30 mg/ml gentamicin LB agar
plates. Double recombinants were checked first screening for
carbellicin (200 mg/ml) susceptibility and afterwards by PCR
amplification and sequencing. For the recycling of the gentamicin
resistance cassettes, plasmid pCM157 was electroporated into the
different mutants. Transformants were selected in 250 mg/ml
tetracycline LB agar plates. One transformant for each mutant was
grown overnight in 250 mg/ml tetracycline LB broth in order to
allow the expression of the cre recombinase. Plasmid pCM157 was
then cured from the strains by successive passages on LB broth.
Selected colonies were then screened for tetracycline (250 mg/ml)
and gentamicin (30 mg/ml) susceptibility and checked by PCR
amplification and DNA sequencing.
PCR, sequencing, and quantification of gene expression
In order to explore the b-lactam resistance mechanisms in the
above described collection of bacterial strains, ampD, ampE, ampR,
ampDh2, ampDh3, creB, creC, creD and dacB genes were amplified by
PCR, using primers described in Table S3, and fully sequenced.
All mutations detected were checked by sequencing a fresh
independent PCR product. Sequencing reactions were performed
with the BigDye Terminator Kit (PE Applied Biosystems, Foster
City, Calif.) and sequences were analyzed on an ABI prism 3100
DNA sequencer (PE Applied Biosystems). Resulting sequences
were then compared (www.ncbi.nih.gov/BLAST) with those of the
wild-type PAO1 strain [33,34].
The levels of expression of ampC, ampD, ampE, ampDh2, ampDh3
and creD were determined by real time RT-PCR with and without
cefoxitin induction. Total RNA from logarithmic-phase-grown
cultures (grown with and without 50 mg/ml cefoxitin) was
obtained with the RNeasy Mini Kit (QIAGEN, Hilden, Germany)
and treated with 2 U of TURBO DNase (Ambion) for 30 min at
37uC to remove contaminating DNA. The reaction was stopped
by the addition of 5 ml of DNase inactivation reagent and the
samples were adjusted to a final concentration of 50 ng/ml. A
500 ng sample of purified RNA was then used for one-step reverse
transcription and real-time PCR amplification using the Quanti-
Tect SYBR Green RT-PCR Kit (QIAGEN, Hilden, Germany) in
a SmartCycler II (Cepheid, Sunnyvale, CA). The primers listed in
Table S3 were used for amplification of ampC, ampD, ampE,
ampDh2, ampDh3, creD, and rpsL (used as reference to normalize the
relative amount of mRNA). In all cases, the mean values of relative
mRNA expression obtained in at least three independent duplicate
experiments were considered.
Susceptibility testing, quantification of b-lactamase
activity, complementation studies, estimation of
mutation rates, and fitness experiments
Minimal inhibitory concentrations (MICs) for ceftazidime,
cefepime, ticarcillin, piperacillin, piperacillin/tazobactam, aztreo-
nam, imipenem, meropenem ciprofloxacin, tobramycin, tetracy-
cline, chloramphenicol and colistin were determined in Mu ¨ller-
Hinton (MH) agar plates using E-test strips (AB Biodisk, Sweden)
following the manufacturers recommendations. b-lactamase spe-
cific activity (nanomoles of nitrocefin hydrolyzed per minute per
milligram of protein) was determined spectrophotometrically on
crude sonic extracts as previously described [6]. To determine the
b-lactamase specific activity after induction, before the preparation
of the crude sonic extracts, the strains were grown in the presence
of 50 mg/ml cefoxitin for 3 h. In all cases, the mean b-lactamase
activity values obtained in three independent experiments were
considered. Complementation experiments were performed fol-
lowing previously described protocols [6]. Briefly, plasmids
pUCPAD (harboring the wild-type ampD gene), pUCPADE
(harboring the complete wild-type ampDE operon) or pUCP24
(cloning vector) were electroporated into the different b-lactam
resistant strains or PAO1 (as control). Additionally, plasmids
pUCPADE2A1, pUCPADE1C5 or pUCPADE2C2 containing a
non functional ampD and a wild-type ampE were electroporated in
selected mutants. Finally, complementation experiments using the
cloned wild-type dacB gene (pUCPdB) were also performed in
selected strains. Transformants were selected in 50 mg/ml
gentamicin LB agar plates. Complementation was considered
positive when the MICs of ceftazidime for the transformants were
at least 3 two-fold dilutions lower than those of the parent strains.
The rates of mutation to high level (16 mg/ml) ceftazidime
resistance were estimated following previously described protocols
(19). To determine the effect on bacterial fitness of particular
resistance mutations, in vitro (LB growth) and in vivo (murine model
of systemic infection) competition experiments were performed
following previously described procedures [27]. Median Compe-
tition Indexes (CIs), defined as the mutant/wild-type ratio, were
calculated from at least 8 independent experiments.
Analysis of whole-genome gene expression
Three independent replicates of PAO1 and of two selected
ceftazidime resistant mutants (1A1 and 2A2) were grown in 10 ml
of LB broth in a 50-ml baffled flask vigorously shaken at 37uCt o
an optical density at 600 nm (OD600) of 1. The cells were
collected by centrifugation (8,000 g for 5 min at 4uC) and total
RNA was isolated using the RNeasy minikit (QIAGEN) following
the manufacturer’s instructions. RNA was dissolved in water and
treated with 2 U of TURBO DNase (Ambion) for 30 min at 37uC
to remove contaminating DNA. The reaction was stopped by the
addition of 5 ml of DNase inactivation reagent. Ten micrograms of
total RNA were checked by running on an agarose gel prior to
cDNA synthesis. cDNA synthesis, fragmentation, labeling and
hybridization were performed according to the Affymetrix
GeneChip P. aeruginosa genome array expression analysis protocol.
Expression analysis was performed as described previously [35].
Only transcripts showing higher than two-fold increases or
decreases were considered as differentially expressed. In all cases
the PPDE (posterior probability for differential expression) was
between 0.999 and 1.
New b-Lactam Resistance Pathway
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in ceftazidime resistance
In order to detect the presence of mutations in genes yet
unknown to be involved in b-lactam resistance, a whole-genome
analysis approach was followed. For this purpose, four ceftazidime
resistant mutants were analyzed and compared with wild-type
PAO1 using a recently described microarray for the discovery of
single nucleotide polymorphisms (SNPs) in P. aeruginosa [20].
Cultures were grown in brain-heart infusion (BHI) medium for
12 h at 37uC in shaking glass flasks at 180 rpm and genomic DNA
was isolated using the DNeasy Blood & Tissue Kit (Qiagen). Cell
lysates were treated with RNase I (Qiagen) to prevent accidental
carryover of RNA to the microarray. Genomic DNA was partially
digested with DNase I (Amersham Biosciences, Piscataway, NJ) to
a fragment size of ,50–250 bp, confirmed by gel electrophoresis,
and fragments were labeled at the 39-ends with biotin-ddUTP
(Roche Diagnostics, Indianapolis, IN) using Terminal deoxynu-
cleotidyl transferase (Roche). Samples were hybridized to an
identical lot of PATA1 arrays [20] for 16 hours at 50uC. After
hybridization the microarrays were washed, stained with SA-PE
and read using an Affymetrix GeneChip fluidic station and
scanner according to Affymetrix standard protocols (Affymetrix,
Santa Clara, CA). Analysis of microarray data was performed
using the Affymetrix GCOS 1.4 to generate the raw data files (cel
data). The raw data files were further analyzed using ‘Tiling
Analysis Software’ (TAS) version 1.1 by Affymetrix.
Supporting Information
Table S1 Characterization of in vitro and in vivo ceftazidime-
resistant mutants. The sequences corresponding to the signal
peptides are shown in italics. SXXK, SXN, and KTG motifs are
shown within boxes and the delimitations of the three domains are
indicated with arrows. Asterisks, colons, and periods indicate
identical, conserved, and semiconserved residues, respectively.
Found at: doi:10.1371/journal.ppat.1000353.s001 (0.06 MB PDF)
Table S2 Strains and plasmids used or constructed in this study
Found at: doi:10.1371/journal.ppat.1000353.s002 (0.06 MB PDF)
Table S3 Primers used in this work
Found at: doi:10.1371/journal.ppat.1000353.s003 (0.04 MB PDF)
Figure S1 Clustal W 2.0.8 multiple-sequence alignment of DacB
from E. coli K12 and P. aeruginosa PAO1
Found at: doi:10.1371/journal.ppat.1000353.s004 (0.03 MB PDF)
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